BioSpace News Archive

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial.

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI) today announced data from the ESMO Asia Congress 2022 and the American Society of Hematology (ASH) Annual Meeting about the use of lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients.

ContraFect Corporation announces that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.0 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement.

Renibus Therapeutics, Inc. today announced the appointment of Asha Ramdas as SVP, Program Management, Technical Operations and Manufacturing.

Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

Envisagenics , an Artificial Intelligence (“AI”)-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Cancer Research Horizons, Cancer Research UK’s innovation engine, and Queen Mary University of London.

CoImmune, Inc. today announced the presentation of results from a Phase I/II clinical trial evaluating CARCIK-CD19.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced demonstration of target engagement and improvement in the signs of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical trial of ADX-629, a first-in-class orally administered investigational new drug candidate.

Tellus Therapeutics announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.

Mawi DNA Technologies announced that it has signed Memorandum of Understanding agreements with the Moroccan Ministry of Investment, Convergence and Evaluation of Public Policies as well as with the Moroccan Ministry of Industry and Commerce to explore a joint venture with Mawi’s local partner BIOTESSIA to establish a state-of-the-art manufacturing facility in Morocco to serve the African market.